Mirae Asset Global Investments Co. Ltd. Has $90,000 Stock Holdings in ImmunityBio, Inc. $IBRX

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 39.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,095 shares of the company’s stock after buying an additional 9,663 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in ImmunityBio were worth $90,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in IBRX. Financial Enhancement Group LLC acquired a new position in shares of ImmunityBio in the 2nd quarter worth approximately $28,000. Slow Capital Inc. acquired a new position in shares of ImmunityBio in the 1st quarter worth approximately $30,000. Compound Planning Inc. acquired a new position in shares of ImmunityBio in the 1st quarter worth approximately $30,000. Vigilare Wealth Management acquired a new position in shares of ImmunityBio in the 2nd quarter worth approximately $31,000. Finally, Xponance Inc. acquired a new position in shares of ImmunityBio in the 1st quarter worth approximately $33,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IBRX shares. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Saturday, September 27th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Wednesday, September 10th. Finally, D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.75.

ImmunityBio Stock Down 3.3%

NASDAQ:IBRX opened at $2.36 on Monday. The company has a fifty day moving average of $2.49 and a 200-day moving average of $2.63. The firm has a market capitalization of $2.32 billion, a P/E ratio of -4.92 and a beta of 0.27. ImmunityBio, Inc. has a twelve month low of $1.83 and a twelve month high of $7.48.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million. On average, analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.